Edge Wealth Management LLC Metacrine, Inc. Transaction History

Edge Wealth Management LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Jan 21, 2022	BUY	$0.64 - $3.83 $7,015 - $41,980	10,961 Added 28105.13%	11,000 $7,000
Q4 2021 Jan 14, 2022	SELL	$0.64 - $3.83 $6,759 - $40,448	-10,561 Reduced 99.63%	39 $7,000
Q2 2021 Jul 23, 2021	BUY	$3.37 - $5.73 $34,711 - $59,019	10,300 Added 3433.33%	10,600 $40,000
Q1 2021 Apr 09, 2021	BUY	$6.2 - $11.0 $1,860 - $3,300	300 New	300 $2,000

Ticker MTCR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,569,500
Description
Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

Get notified when there are updates to the investment portfolio of Edge Wealth Management LLC, based on Form 13F filings with the SEC.

Stay updated on Edge Wealth Management LLC with notifications on news.